Skip to main content
construction release_alert
Scholars@Duke will be undergoing maintenance April 11-15. Some features may be unavailable during this time.
cancel

Pentavalent HIV-1 vaccine protects against simian-human immunodeficiency virus challenge.

Publication ,  Journal Article
Bradley, T; Pollara, J; Santra, S; Vandergrift, N; Pittala, S; Bailey-Kellogg, C; Shen, X; Parks, R; Goodman, D; Eaton, A; Balachandran, H ...
Published in: Nat Commun
June 8, 2017

The RV144 Thai trial HIV-1 vaccine of recombinant poxvirus (ALVAC) and recombinant HIV-1 gp120 subtype B/subtype E (B/E) proteins demonstrated 31% vaccine efficacy. Here we design an ALVAC/Pentavalent B/E/E/E/E vaccine to increase the diversity of gp120 motifs in the immunogen to elicit a broader antibody response and enhance protection. We find that immunization of rhesus macaques with the pentavalent vaccine results in protection of 55% of pentavalent-vaccine-immunized macaques from simian-human immunodeficiency virus (SHIV) challenge. Systems serology of the antibody responses identifies plasma antibody binding to HIV-infected cells, peak ADCC antibody titres, NK cell-mediated ADCC and antibody-mediated activation of MIP-1β in NK cells as the four immunological parameters that best predict decreased infection risk that are improved by the pentavalent vaccine. Thus inclusion of additional gp120 immunogens to a pox-prime/protein boost regimen can augment antibody responses and enhance protection from a SHIV challenge in rhesus macaques.

Duke Scholars

Altmetric Attention Stats
Dimensions Citation Stats

Published In

Nat Commun

DOI

EISSN

2041-1723

Publication Date

June 8, 2017

Volume

8

Start / End Page

15711

Location

England

Related Subject Headings

  • Simian immunodeficiency virus
  • Simian Immunodeficiency Virus
  • Regression Analysis
  • Recombinant Proteins
  • Protein Binding
  • Predictive Value of Tests
  • Phylogeny
  • Phagocytosis
  • Neutralization Tests
  • Mutation
 

Citation

APA
Chicago
ICMJE
MLA
NLM
Bradley, T., Pollara, J., Santra, S., Vandergrift, N., Pittala, S., Bailey-Kellogg, C., … Haynes, B. F. (2017). Pentavalent HIV-1 vaccine protects against simian-human immunodeficiency virus challenge. Nat Commun, 8, 15711. https://doi.org/10.1038/ncomms15711
Bradley, Todd, Justin Pollara, Sampa Santra, Nathan Vandergrift, Srivamshi Pittala, Chris Bailey-Kellogg, Xiaoying Shen, et al. “Pentavalent HIV-1 vaccine protects against simian-human immunodeficiency virus challenge.Nat Commun 8 (June 8, 2017): 15711. https://doi.org/10.1038/ncomms15711.
Bradley T, Pollara J, Santra S, Vandergrift N, Pittala S, Bailey-Kellogg C, et al. Pentavalent HIV-1 vaccine protects against simian-human immunodeficiency virus challenge. Nat Commun. 2017 Jun 8;8:15711.
Bradley, Todd, et al. “Pentavalent HIV-1 vaccine protects against simian-human immunodeficiency virus challenge.Nat Commun, vol. 8, June 2017, p. 15711. Pubmed, doi:10.1038/ncomms15711.
Bradley T, Pollara J, Santra S, Vandergrift N, Pittala S, Bailey-Kellogg C, Shen X, Parks R, Goodman D, Eaton A, Balachandran H, Mach LV, Saunders KO, Weiner JA, Scearce R, Sutherland LL, Phogat S, Tartaglia J, Reed SG, Hu S-L, Theis JF, Pinter A, Montefiori DC, Kepler TB, Peachman KK, Rao M, Michael NL, Suscovich TJ, Alter G, Ackerman ME, Moody MA, Liao H-X, Tomaras G, Ferrari G, Korber BT, Haynes BF. Pentavalent HIV-1 vaccine protects against simian-human immunodeficiency virus challenge. Nat Commun. 2017 Jun 8;8:15711.

Published In

Nat Commun

DOI

EISSN

2041-1723

Publication Date

June 8, 2017

Volume

8

Start / End Page

15711

Location

England

Related Subject Headings

  • Simian immunodeficiency virus
  • Simian Immunodeficiency Virus
  • Regression Analysis
  • Recombinant Proteins
  • Protein Binding
  • Predictive Value of Tests
  • Phylogeny
  • Phagocytosis
  • Neutralization Tests
  • Mutation